Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion

Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion

San Diego, Calif.-based Halozyme Therapeutics is purchasing Ewing, N.J.-headquartered Antares Pharma in a deal valued at approximately $960 million.

The acquisition will give Halozyme access to Antares’ Enhanze enzyme-based drug delivery technology and the company’s auto injector, which has potential uses for delivering a broad range of medications.

Antares has already developed several self-injection products, including the injectable testosterone drugs Xyosted (testosterone enanthate) and Tlando (testosterone undecanoate).

The transaction is expected to close in the first half of 2022.

Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products and technologies. The Company develops, manufactures, and commercialize, for itself or with partners, therapeutic products using its drug delivery systems. Its Epinephrine Injection USP products is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients.

April 14, 2022

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company